The Science of Selection: Pharmacist Initiatives in Endometrial Cancer Care

In ‘The Science of Selection: Pharmacist Initiatives in Endometrial Cancer Care,’ the expert Oncology Pharmacists explored the following critical questions:

How can pharmacist-led education initiatives improve awareness of biomarker testing and treatment selection in endometrial cancer?

When should pharmacists advocate for an adjustment in immunotherapies in patients with endometrial cancer?

The panelists examined the essential role of the pharmacist in making biomarker testing accessible and interpretable within the clinical setting. Justina Salib and Erin Zacholski emphasized the importance of educating students, residents, and the broader care team on the nuances of molecular versus genetic testing (e.g., MMR vs. MSI) to ensure precise therapy selection. Jennifer MacDonald shared practical strategies for collaborating with pathology to expedite specific results, such as PD-L1 or dMMR, which are often required for insurance approval. The experts also discussed the critical "give or do not give" decision-making process for immunotherapies, highlighting that pharmacists should advocate for holding therapy at the first sign of an immune-related adverse event (irAE) to prevent progression to higher-grade toxicities.

Throughout the conversation, the experts provided a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the final episode ‘Managing Toxicities and Shaping the Next 5 Years of Endometrial Cancer Care,’ the panelists explore the following critical questions how to monitor and manage adverse events associated with immunotherapies, as well as the evolving role of the pharmacist.